Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	43 hospital inpatients with acute gout confirmed by synovial fluid examination, aged 55–91 years, 40/43 (93%) men	Proportion of people with nausea, diarrhoea, or vomiting 22/22 (100%) with colchicine 5/21 (24%) with placebo	Significance assessment not reported
RCT 3-armed trial	575 people who were able to start treatment within 12 hours of a gout attack, randomised between attacks; 184 people who subsequently developed acute gout included in analysis (see Further information on studies)	Adverse effects 40/52 (77%) with high-dose colchicine (4.8 mg orally, given over 6 hours) 16/58 (27%) with placebo	OR 9.0 95% CI 3.8 to 21.2	Large effect size	placebo
RCT 3-armed trial	575 people who were able to start treatment within 12 hours of a gout attack, randomised between attacks; 184 people who subsequently developed acute gout included in analysis (see Further information on studies)	Adverse effects 27/74 (37%) with low-dose colchicine (1.8 mg orally, given over 1 hour) 16/58 (27%) with placebo	OR 1.5 95% CI 0.7 to 3.2		Not significant
RCT 3-armed trial	575 people who were able to start treatment within 12 hours of a gout attack, randomised between attacks; 184 people who subsequently developed acute gout included in analysis (see Further information on studies)	Gastrointestinal adverse effects 40/52 (77%) with high-dose colchicine given over 6 hours (4.8 mg orally) 12/59 (20%) with placebo	OR 13.1 95% CI 5.3 to 32.3	Large effect size	placebo
RCT 3-armed trial	575 people who were able to start treatment within 12 hours of a gout attack, randomised between attacks; 184 people who subsequently developed acute gout included in analysis (see Further information on studies)	Gastrointestinal adverse effects 19/74 (26%) with low-dose colchicine given over 1 hour (1.8 mg orally) 12/59 (20%) with placebo	OR 1.4 95% CI 0.6 to 3.1		Not significant
RCT 3-armed trial	575 people who were able to start treatment within 12 hours of a gout attack, randomised between attacks; 184 people who subsequently developed acute gout included in analysis (see Further information on studies)	Severe intensity adverse effects 10/52 (19%) with high-dose colchicine (4.8 mg orally, given over 6 hours) 1/59 (2%) with placebo	OR 13.8 95% CI 1.7 to 112	Large effect size	placebo
RCT 3-armed trial	575 people who were able to start treatment within 12 hours of a gout attack, randomised between attacks; 184 people who subsequently developed acute gout included in analysis (see Further information on studies)	Severe intensity adverse effects 0/74 (0%) with low-dose colchicine (1.8 mg, given over 1 hour) 1/59 (2%) with placebo	Significance assessment not reported